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Subsets of long-lived, tumor-initiating stem cells
often escape cancer therapies. However, sources
and mechanisms that generate tumor heterogeneity
and drug-resistant cell population are still unfolding.
Here, we devise a functional reporter system to
lineage trace and/or genetic ablate signaling in
TGF-b-activated squamous cell carcinoma stem
cells (SCC-SCs). Dissecting TGF-b’s impact on
malignant progression, we demonstrate that TGF-b
concentrating near tumor-vasculature generates
heterogeneity in TGF-b signaling at tumor-stroma
interface and bestows slower-cycling properties to
neighboring SCC-SCs. While non-responding proge-
nies proliferate faster and accelerate tumor growth,
TGF-b-responding progenies invade, aberrantly
differentiate, and affect gene expression. Intrigu-
ingly, TGF-b-responding SCC-SCs show increased
protection against anti-cancer drugs, but slower-
cycling alone does not confer survival. Rather,
TGF-b transcriptionally activates p21, which stabi-
lizes NRF2, thereby markedly enhancing glutathione
metabolism and diminishing effectiveness of anti-
cancer therapeutics. Together, these findings estab-
lish a surprising non-genetic paradigm for TGF-b
signaling in fueling heterogeneity in SCC-SCs, tumor
characteristics, and drug resistance.INTRODUCTION
Most tumors are of a clonal origin but often exhibit heterogeneity
in phenotypic and functional properties including proliferation,
morphology, motility, and differentiation. Such heterogeneity
has also been implicated in the ability to survive therapy and
seed metastases (Hanahan and Weinberg, 2011). Cumulative
mutations resulting from genomic instability certainly produce
heterogeneity (Greaves and Maley, 2012). However, develop-
mental diversity of cell types is accomplished without genetic
alterations, raising the possibility that cellular diversity within tu-
mors may also arise from non-genetic factors. Contributing var-
iations might come from the tumor microenvironment, which cantransmit gradients of signaling factors, oxygen, and metabolites
to tumor cells depending upon their proximity to the local sour-
ces (Meacham andMorrison, 2013; Kreso and Dick, 2014). While
the hypothesis is attractive, experimental evidence is lacking,
and non-genetic mechanisms that drive tumor heterogeneity
remain largely unknown.
Irrespective of the basis for tumor heterogeneity, the long-
lived capacity of tumor-initiating stem cells (SCs) to self-renew,
initiate, and propagate cancers place these cells at the roots of
diversity. Furthermore, SCs are often few in number and can
exist in slow-cycling states, which has led to speculation that
cancer SCs may be the source of recurrence following anti-can-
cer therapy (Hope et al., 2004; Berns, 2005; Notta et al., 2011;
Visvader and Stingl, 2014). Another potentially intertwined factor
is the need for long-lived SCs to adjust their metabolism in order
to withstand stress and reactive oxygen species (ROS) (Diehn
et al., 2009). In turn, such metabolic reprogramming can alter
cellular behavior and lead to cancer progression (Bigarella
et al., 2014). To this end, variations in cycling rates and/or local
microenvironments could generate metabolic heterogeneities
in cancer SCs, which could ultimately affect tumor heterogeneity
and drug resistance.
An excellent tumor model for addressing these issues is squa-
mous cell carcinoma (SCC). Among the most common and life-
threatening cancers world-wide, SCCs exhibit high rates of
tumor recurrence following anti-cancer therapy. Both function-
ally and molecularly, populations enriched for SCC-SCs have
been identified, purified, and characterized. These SCC-SC-en-
riched populations represent 1%–5% of the tumor and reside
at the tumor-stroma interface. They are typified by elevated in-
tegrins, and other markers, e.g. CD34, CD44, and SOX2 (Malan-
chi et al., 2008; Schober and Fuchs, 2011; Lapouge et al., 2012).
They also express VEGFA, suggestive of enrichment at the
vasculature (Beck et al., 2011). Interestingly, heterogeneity,
particularly in proliferative rates, exists within SCC-SC-enriched
populations (Schober and Fuchs, 2011). Whether a slow-cycling
property allows some SCs to escape chemotherapy and
contribute to cancer recurrence has not been explored.
Notably, SCC-SC numbers increase by 10-fold when TbRII,
an essential component of the transforming growth factor b
(TGF-b) transmembrane receptor, is abrogated (Schober and
Fuchs, 2011). TGF-b is a well-established inhibitor of normal
epithelial cell proliferation, and conditional ablation of Tgfbr2
predisposes epithelial tissues to cancer (Lu et al., 2006; Ijichi
et al., 2006; Mun˜oz et al., 2006; Guasch et al., 2007).Cell 160, 963–976, February 26, 2015 ª2015 Elsevier Inc. 963
Paradoxically, although elevated TGF-b signaling in skin pre-
vents chemical induction of benign papillomas, TGF-b enhances
their malignant conversion to SCCs and promotes metastasis
(Cui et al., 1996; Massague´, 2012).
Researchers often attribute these seemingly distinct effects
of TGF-b to cumulative genetic changes during tumorigenesis.
However, since cycling rates of SCs are heterogeneous within
an SCC and since SC numbers increase in the absence
of TGF-b signaling, we posited that heterogeneity in TGF-
b-responsiveness might exist within SCC progenitors, and
might simultaneously restrict their proliferation and promote
invasion and malignant transformation. If so, TGF-b-mediated
differences in cycling rates of SCC-SCs could contribute to
metabolic heterogeneity, as well as ultimately, heterogeneity
in response to anti-cancer therapies. Elucidating how TGF-b
functions in cancer progression and metastasis is a prerequisite
for ascertaining whether disrupting this pathway is prudent for
metastatic therapeutics when its tumor suppressive features
might co-exist.
The TGF-b signaling pathway has been extensively studied.
When latent TGF-b ligands are processed and activated, they
can bind to TbRII, which phosphorylates TbRI, the other essential
component of this bipartite transmembrane receptor. Activated
TbRI propagates the signal by phosphorylating intracellular
downstream effectors, SMAD2 and SMAD3 (SMAD2/3), which
complex with SMAD4, translocate to the nucleus and bind to
specific DNA sequence motifs called SMAD-binding elements
(SBEs). Upon binding, pSMAD2/3-SMAD4 complexes interact
with additional transcriptional regulators to transactivate TGF-
b-responsive target genes (Massague´, et al., 2005; Mullen
et al., 2011).
The ability of TGF-b signaling to activate target genes enables
the pathway to impact diverse cellular processes including not
only proliferation but also differentiation, migration, apoptosis,
and ECM remodeling (Derynck and Miyazono, 2008; Massague´,
2012; Oshimori and Fuchs, 2012a). Important questions now
emerge regarding TGF-b’s ability to unleash its varied and tem-
poral effects on tumor progression. Do TGF-b’s seemingly
opposing actions on proliferation and invasion act sequentially
or do they act simultaneously in tumor progression? Are these
dissimilar events dependent upon progressively distinct genetic
states that emerge during malignancy? Does TGF-b contribute
to heterogeneity in the tumor microenvironment and, if so,
how? Can heterogeneity in TGF-b signaling impact SCC-SCs
differentially and might this allow some cancer SCs to escape
anti-cancer drugs? If so, is it because of its ability to impact pro-
liferation rates, affect metabolic states and/or alter the expres-
sion of key target genes?
To tackle these issues, we devised a strategy tomonitor, track,
and modify TGF-b signaling in mouse skin during malignant pro-
gression. In so doing, we’ve been able to delineate the temporal
functions of TGF-b in SCCs as they develop and progress. Com-
bined with transcriptional profiling, molecular, biochemical,
and genetic studies, we unearth important functions for TGF-b
signaling during the process and unveil its impact not only on
cancer SC proliferation but also on the emergence of tumor
heterogeneity and anti-cancer drug resistance. Moreover, we
show that metabolic reprogramming, an emerging hallmark of964 Cell 160, 963–976, February 26, 2015 ª2015 Elsevier Inc.cancer, is also integrally linked to TGF-b-mediated effects on
cancer SCs, and that TGF-b-regulated metabolism in particular
plays a critical role in the divergent responses to anti-cancer
therapies.
RESULTS
An In Vivo Reporter System for Lineage Tracing and
Manipulating TGF-b Responding Cells During Malignant
Progression
To identify putative TGF-b-responding cells within skin tumors,
we first performed anti-phospho (active) SMAD2 immunofluo-
rescence on mouse skin at various stages following classical
carcinogenic protocols with tumor-initiator 7,12-dimethyl-
benz(a)anthracene (DMBA) and tumor-promoter 12-O-tetrade-
canoyl-phorbol-13-acetate (TPA) (Figure 1A). As reported previ-
ously (Oshimori and Fuchs, 2012b), nuclear pSMAD2 was barely
detectable in interfollicular epidermis. In normal skin, it appeared
transiently in follicular stem cells (SCs) at the start of a new hair
cycle. As benign papillomas formed, pSMAD2 immunolabeling
remained low in epithelium but was found in some stromal cells.
As papillomas transitioned to malignant SCC, marked nuclear
pSMAD2 appeared in epithelial cells at the invasive tumor front.
Keratin 14 (K14)-Cre-mediated ablation of Tgfbr2 specifically in
skin epithelium resulted in complete loss of pSMAD2 in SCCs,
but not surrounding stroma. These findings underscored the ef-
ficacy of the antibody and the dependence of SMAD2/3 activa-
tion in SCCs on TGF-b/TbRI/II signaling, rather than pathways
triggered by Nodal or Activins.
To monitor TbRI/II–pSMAD2 signaling in vivo, we designed
a lentiviral (LV) TGF-b reporter system that used an enhancer
composed of multimerized pSMAD2/3 binding elements (SBE)
to drive a P2A-based bicistronic transcript encoding nuclear
(NLS) mCherry and tamoxifen (Tam)-activatable CreER recom-
binase (herein called TGFb-CreER). We inserted a polymerase
III-driven promoter in the opposite direction to simultaneously
drive an shRNA to achieve knockdown (KD) of a desired tran-
script (Figure S1A). We first tested this reporter in primary kera-
tinocytes (10MKs) cultured from Rosa26-lox-STOP-lox-EYFP
Cre reporter (Rosa-YFP) mice bred on either a Tgfbr2+/+ or
Tgfbr2fl/fl background (Figure S1B). Upon TGF-b treatment, re-
porter-transduced 10MKs expressed NLS-mCherry. Tam then
activated CreER in TGF-b-responding MKs, leading to constitu-
tive Rosa-YFP expression. Upon Tgfbr2 ablation, cells lost TGF-
b responsiveness, and in turn extinguished NLS-mCherry
expression (Figure S1B).
We brought the TGF-b reporter system into an in vivo setting
by injecting LV into the amniotic sac of E9.5 mouse embryos.
This in utero method allowed titer-dependent (1/>90%) selec-
tive transduction of the unspecified surface epithelial progenitors
that give rise to skin epithelia (Beronja et al., 2010). By adding a
reverse tetracycline transactivator (rtTA) cassette (PGK-rtTA3)
to our LV TGF-b reporter construct, we could transduce TRE-
Hras1G12V transgenic mice (Chin et al., 1999) and then induce
oncogenic HRasG12V with doxycycline (Doxy) (Figure 1B).
In the first experiment, we crossed TRE-Hras1G12V and TRE-
H2BGFPmice, and sparsely delivered TGF-b reporter to surface
ectoderm of transgenic embryos. Postnatally, doxy-dependent
Figure 1. Lentiviral TGF-b Reporter System for Probing Malignant Transformation In Vivo
(A) pSMAD2 immunolocalization in normal mouse skin and at different stages of DMBA-TPA-induced malignant progression to SCC. Integrin a6 denotes the
boundary of tumor epithelia (Tu) and stroma (St). IFE: interfollicular epidermis, HF: hair follicle.
(B) Schematic of LV-mediated in vivo TGF-b reporter and KO/KD system. NLS-mCherry and CreER are under the control of TGF-b signaling. shRNA and rtTA3
transcription factor are under constitutive promoter regulation. LV transduction of surface epithelium of live E9.5 TetO-HrasG12V X Rosa-YFP embryos was
achieved by in utero ultrasound-guided microinjection into the amniotic sac. Doxy-induction of HRasG12V initiates tumorigenesis. When desired, CreER is
activated by Tam to induce recombination-dependent Rosa-YFP.
(C) Epifluorescence detection of TGF-b–pSMAD2 signaling in HRasG12V SCC.
(D) Limit-dilution orthotopic transplantation of primary tumor basal cells ± TGF-b reporter activity (103 and 104 cells; n=8, 105 cells; n=3).
(E) Epifluorescent TGF-b reporter activity with pan-anti-TGF-b and anti-a6 immunofluorescence shows that basal tumor cells with high TGF-b reporter activity are
juxtaposed to stroma with high TGF-b (right). Note heterogeneity demarcated by vertical dotted line.
Scale bars, 50 mm. See also Figure S1.HRasG12V induction occurred exclusively in LV-transduced
cells. Within 1–2 months, papillomas formed, which often rapidly
progressed to SCC in all or part of the tumor. Tumor epithelia
were GFP+, reflecting their derivation from rtTA-expressing,
LV-transduced cells (Figure S1C). Additionally, the low levels of
virus used (MOI<<1) suggests that these tumors were clonally
derived.
In remaining studies, we used TRE-Hras1G12V X Rosa-YFP X
Tgfbr2 (+/fl or fl/fl) mice. TGF-b reporter activity (NLS-mCherry)
co-localized with pSMAD2 and was particularly intense in a sub-
set of basal tumor cells at invasive fronts (Figures 1C and S1D).
Serial transplantation assays previously revealed that the tumor-
stromal interface is where cells exist that have long-term, tumor-
initiating potential, defined as SCC-SCs (Schober and Fuchs,
2011; Lapouge et al., 2012). To addresswhether the heterogene-ity of TGF-b signaling at this interface might be relevant to
SCC-SCs, we used fluorescence-activated cell sorting (FACS)
to fractionate CD44+a6hi basal tumor cells according to mCherry
expression. mCherry+ cells frequently expressed SC marker
CD34 (Figure S1E). In vitro, the colony forming efficiency of
TGF-b-responding basal cells was higher than non-responding
counterparts, while in direct transplantation assays, FACS-puri-
fied TGF-b reporter+ basal cells displayed 5X higher tumor-
initiating frequency than reporterneg counterparts (Figures 1D
and S1F). Together, these data indicate that the TGF-b-respond-
ing subset of CD44+CD34+a6hi basal tumor cells was enriched
for SCC-SCs.
Immunostaining revealed heterogeneity in TGF-b ligand distri-
bution in the stroma that correlated well with basal tumor cell
heterogeneity in TGF-b signaling (Figure 1E). Of the various cellCell 160, 963–976, February 26, 2015 ª2015 Elsevier Inc. 965
Figure 2. TGF-b Signaling-Driven Lineage Tracing during Tumor Development
(A) Experimental scheme and representative images of TGF-b signaling-driven lineage tracing. Once tumors form (>7 mm), NLS-mCherry is detected in TGF-
b-responding transduced cells (Tam-). A single i.p. injection of low-dose Tam elicits Rosa-YFP recombination in a small subset of these cells within 2d post-Tam
injection (2dpi). Note YFP/mCherry double-positive cell at invasive front. YFP-marked cells undergo clonal expansion, evident at 7 and 14 dpi, and now inde-
pendent of TGF-b reporter activity (right). Note difference in clonal expansion rate and morphology based upon whether the initial marked cell is from a tumor
initiated on a Tgfbr2 (fl/+) (top) or (fl/fl) (bottom) genetic background.
(B) Immunolabeling (left) and quantifications (right) show that suprabasal differentiation marker K10 preferentially marks YFP+ clones (n=19 analyzed) derived
from K14-CreER-induced basal tumor cells. Note that TGFb-CreER-induced lineage tracing marks TGF-b-responding basal cells that yield YFP+K10neg clones
(n=21). Data are mean ± SEM.
(C) S-phase analysis during lineage tracing. BrdU or EdUwas administered at 2 or 7 dpi, respectively (see Figures S2H and S2I), and YFPneg and YFP+ basal tumor
cells were quantified for nucleotide incorporation (n = 11–15).
Data are box-and-whisker plots. Scale bars, 50 mm. See also Figure S2.types surrounding the tumor, TGF-b immunolabeling best
overlapped with CD11b+Ly6C+ monocytic myeloid cells (Fig-
ure S1G), in agreement with a prior report that human peripheral
blood monocytes secrete TGF-b (Grotendorst et al., 1989).
Interestingly, TGF-b+ cells often localized near vasculature, while
nuclear pSMAD2 gave a complementary pattern in nearby
SCC-SCs (Figures S1G and S1H). The spatial relation between
epithelial TGF-b reporter activity and tumor vasculature was
exemplified by three-dimensional (3D) microscopic imaging of
the tumor-stromal interface (Movies S1 and S2). These results
suggest that TGF-b ligand distribution coincides with vascula-
ture and immune cell heterogeneity in tumor microenvironment,
and this in turn, generates regional TbRI/II–pSMAD2 signaling
within nearby malignant epithelial progenitors at the tumor-
stroma interface.966 Cell 160, 963–976, February 26, 2015 ª2015 Elsevier Inc.Lineage Tracing Unveils Distinct Behaviors of
TGF-b-Responding Versus Non-Responding SCC-SCs
To track the fate of TGF-b-responsive cells during early tumor
progression in vivo, we performed TGF-b signaling-dependent
lineage tracing by transducing our TGF-b reporter at low MOI
as before and then administering Doxy at birth to induce tumor-
igenesis. Once tumors reached7mm in size, a single low-dose
of Tam was then administered systemically to trigger 24 hr of
CreER activity in a small subset of TGF-b-reporter-activated tu-
mor cells (diagram in Figure 2A). Prior to Tam injection, emerging
tumors showed mCherry but no YFP, underscoring the depen-
dency of mCherry/CreER bicystronic expression on TGF-b but
the reliance of CreER activation on Tam.
At 2 days post-Tam injection (dpi), single or small clusters
of 2–4 YFP+ cells were found at the tumor-stroma interface
(Figure 2A). YFP+TbRII+ clones grew markedly over the subse-
quent 2 weeks and showed enrichment at invasive protrusions.
Surprisingly, however, cells within these clones were highly scat-
tered (shown).
On the Tgfbr2fl/fl background, Tam resulted in Tgfbr2 ablation
specifically in the few randomTGF-b-responding tumor cells that
had activated CreER and YFP. YFP+TbRIInegpSMAD2neg cells
underwent clonal growth faster, and clones were more tightly
packed and less intrusive than TbRII+ counterparts (Figure 2A).
Importantly, because we ablated Tgfbr2 in TGF-b-responsive
cells, this difference was not attributable to microenvironmental
heterogeneity but rather to intrinsic SC differences arising from
loss of TGF-b signaling.
The increased scattering and invasiveness of clones derived
from TGFb-responsive tumor cells was accompanied by several
features typically associated with epithelial to mesenchymal
transition (EMT), including an elongated cell shape, reduced E-
cadherin, and enhanced ZEB2 and HMGA2 (Figures S2A–S2D,
Movie S3) (Thuault et al., 2006; Hanahan and Weinberg, 2011).
By 3D reconstruction of Z-stack images, the clonal nature of
the expanding colonies was still discernable, as was their close
proximity to tumor vasculatures (Movie S4).
Serendipitously, additional functional lineage tracing unveiled
a role for TGF-b signaling in generating aberrant differentiation
during malignant progression. When Tam was given to tumors
from K14-CreER X Rosa-YFP X TRE-HrasG12V mice transduced
with LV-rtTA3, many YFP+ clones from total basal tumor cells
(K14hi/K5+) displayed a differentiation keratin K10 suprabasally
(Figure 2B). By contrast, in TGFb-CreER-driven YFP+ clones,
K10 was rarely detected, and leading edge cells showed
reduced K5 (Figure S2E). Conversely, K13 and K18, ectopically
induced in skin SCCs (Nischt et al., 1988; Yamashiro
et al., 2010), were readily detected in TGFb-CreER-driven YFP+
clones, but not in most K14-CreER-driven ones nor in unmarked,
TGFb-non-responsive basal tumor cells from TGFb-CreER
animals (Figures S2F and S2G).
As shown in Figures 2C and S2H, fewer TGF-b-responding
(YFP+) basal cells were in S-phase relative to TGF-b non-re-
sponding (YFPneg) basal cells. Interestingly, however, as YFP+
basal cells clonally expanded, their SCs remained less prolifera-
tive, suggestive of a prolonged slower-cycling state within the
TGF-b lineage. By contrast, mosaic YFP+TbRIIneg basal clones
showed high cycling rates compared to their YFPnegTbRII+
neighbors (Figures 2C and S2I).
Taken together, our in vivo data provided compelling evidence
that TGF-b signaling is directly responsible for generating a
pool of slower-cycling SCC-SCs. Moreover, these data further
suggest that TGF-b is involved in a non-genetic mechanism
that underlies the emergence of tumor heterogeneity at perivas-
cular regions and which leads to simultaneous invasiveness, cell
dissemination, and aberrant differentiation, at the expense of SC
proliferation and tumor growth.
TGF-b Protects SCC Progenitors From Anti-Cancer
Drugs
It has long been suggested that slower-cycling SCs might be
refractory to chemotherapeutic anti-proliferative cancer drugs.
One of the most widely used anti-cancer drugs, cisplatin [cis-di-amminedichloroplatinum (II)], is the standard chemotherapy for
head and neck SCC, and has been used to treat advanced cuta-
neous SCC. However, tumor recurrence is a major problem.
To test whether TGF-b signaling might be involved in drug
resistance, we first conducted a series of in vitro experiments.
We prepared HRasG12V-expressing 10MKs from Tgfbr2fl/fl X
Rosa-YFP mice and transduced them with TGF-b reporter-
CreER. After TGF-b1 ± Tam, YFPnegTbRII+ and YFP+TbRIIneg
isogenic MKs were co-cultured to assess phenotypes under
identical conditions. As expected, TGF-b1 caused reporter acti-
vation and growth arrest in YFPnegTbRII+, but not YFP+TbRIIneg
MKs (Figures 3A and 3B).
Cisplatin exerts its cytotoxicity by forming DNA-cisplatin
adducts that are recognized by DNA damage recognition com-
plexes which trigger apoptosis (Kelland, 2007). Consistent with
these effects, cisplatin caused apoptotic rounding and g-H2AX
(marking DNA double-strand breaks) throughout proliferating
cultures (Figures 3C and 3D). Interestingly, after exposure to
TGF-b1 for 24–36 hr, most YFPnegTbRII+ cells remained spread,
with markedly reduced g-H2AX compared to YFP+TbRIIneg
counterparts. Quantifications with active Caspase-3 (AcCasp3)
indicated that TGF-b1 pre-treatment significantly reduced
cisplatin-induced apoptotic death (Figure 3E). Moreover, an anti-
body recognizing DNA-cisplatin adducts showed preferential
immunolabeling of YFP+TbRIIneg MKs in cisplatin-treated cul-
tures (Figure 3F). These results suggested that TGF-b signaling
enables cultured SCC-SCs to better withstand cisplatin-induced
apoptosis.
TGF-b-Responding SCC Progenitors Are Responsible
for Drug Resistance and Tumor Recurrence
To test TGF-b’s protective qualities in vivo, we challenged
tumor-bearing TGF-b reporter mice with systemic cisplatin.
While few AcCasp3+ cells were detected in saline-injected con-
trol mice, cisplatin significantly increased apoptosis within skin
tumor cells. Strikingly, fewer basal tumor cells with active TGF-
b signaling were apoptotic (Figure 4A and Movie S5).
If TGF-b signaling contributes to drug therapy failure, TGF-
b-responding cells should remain during treatment and outgrow
their non-resistant peers over time. To test this hypothesis,
we conducted TGF-b reporter-driven lineage tracing on TbRII+H-
RasG12V tumors during systemic cisplatin treatment. To ensure
that we were monitoring TGF-b reporter+ progeny, we carried
out Tam treatment (3 doses, 12 hr each) until 1.5 days prior to
cisplatin administration. Relative to saline controls, cisplatin in-
jections resulted in a striking reduction in tumor volume within
10–12 days (Figure S3A).
Most notably, the remaining tumors, some of which already
showed recurrent growth (Figure S3A), were disproportionately
maintained by YFP+ progenies of TGF-b-responding cells (Fig-
ures 4B and 4C). This was notable since recurrent tumors still ex-
hibited TGF-b reporter activity, and since even though overall
proliferative rates of YFP+ SCC-SCs were elevated in these
recurring tumors, the TGF-b reporter+ cohort of basal tumor cells
still remained slower-cycling relative to TGF-b-reporterneg coun-
terparts (Figures 4C and 4D). Finally, as in the primary tumor
clones derived from TGF-b reporter+ lineages, K10 was broadly
absent in YFP+ suprabasal cells, suggesting that recurringCell 160, 963–976, February 26, 2015 ª2015 Elsevier Inc. 967
Figure 3. Active TGF-b Signaling in Basal Tumor Cells Increases Their Protection against Cisplatin-Induced Apoptosis
(A) Experimental scheme to derive isogenic HRasG12V-expressing YFPnegTbRII+ and YFP+TbRIIneg MKs from 10 cultures. (Right) Epifluorescence of cultures ±
TGF-b1. Note that only YFPnegTbRII+ cells are TGF-b reporter+ (mCherry+).
(B) Growth curves of TbRII+ and TbRIIneg cells ± 100pM TGF-b1. Data are mean ± SEM.
(C) Immunofluorescence of BSA- or TGF-b1-pretreated (36 hr) YFPnegTbRII+ and YFP+TbRIIneg MKs treated 10 hr with cisplatin. Note that YFP+TbRIIneg MKs
frequently displayed signs of apoptotic rounding.
(D) g-H2AX detection of DNA double-strand breaks induced by cisplatin treatment. Note that both YFPnegTbRII+ and YFP+TbRIIneg MKs show g-H2AX signal in
control, but TGF-b1 selectively spares TbRII+ cells, which remain spread.
(E) Quantifications of AcCasp3+ cells in the same experiment as in (C) and (D) (n=15 microscopic image fields). Data are box-and-whisker plots.
(F) Immunodetection of adduct formed between cisplatin and DNA. Note that YFP+TbRIIneg cells have more cisplatin-modified DNA (red). Anti-tubulin (white).
Scale bars, 50 mm.tumors were enriched for malignant TGF-b–pSMAD2-signaling
basal cells that had survived cisplatin treatment (Figure 4E).
If TGF-b signaling confers increased cisplatin protection to
SCC-SCs in vivo, then ablating TGF-b signaling in these cells
should confer increased sensitivity to apoptosis. To test this hy-
pothesis, we repeated the experiment shown in Figure 4B, this
time on Tgfbr2+/fl (control) and Tgfbr2fl/fl (test) backgrounds. To
ensure optimal Tgfbr2 allele targeting, we extended Tam treat-
ments until 3d prior to cisplatin. As shown in Figure 4F, loss of
TGF-b signaling resulted in enhanced cisplatin sensitivity.
We obtained similar results when we transduced human SCC
lines with TGF-b reporter LV and xenografted them inNudemice
(Figure S3B). Upon cisplatin treatment, TGF-b reporterneg human
basal tumor cells showed greater sensitivity than their TGF-b re-
porter+ counterparts (Figure 4G). When the experiment was
repeated with TGF-b inhibitor LY364947, a dramatic increase
in cisplatin sensitivity was observed (Figure 4H and S3C).
Together, these findings suggest that both in mouse and human,
TGF-b signaling is heterogeneous and increases protection of
SCC-SCs against cisplatin.
Transcriptome Analysis Uncovers a Link between TGF-b
Signaling and Glutathione Metabolism in SCC Stem
Cells
The ability of TGF-b signaling to confer enhanced survival
to SCC-SCs of cisplatin-treated tumors was consistent with
the cancer stem cell hypothesis for tumor recurrence. A priori,968 Cell 160, 963–976, February 26, 2015 ª2015 Elsevier Inc.TGF-b’s power could arise from its impact on slow-cycling
behavior and/or its effect on transcription. To gain further
insights, we used FACS and RNA sequencing (RNA-seq) to
purify, transcriptionally profile and compare TGF-b-responding
(mCherry+) versus non-responding (mCherryneg) SC populations
from >7 mm HRasG12V-induced tumors (Figures S4A–S4C).
Our purification scheme was optimized by depleting stromal
cell types and dead cells, and then positively selecting for high
surface expression of markers of SCC-SCs.
Independent duplicates yielded highly reproducible RNA-seq
data (Figure 5A). Dendrogram analysis indicated that despite
similarities across SCC-SC profiles, TGF-b reporter+ samples
clustered together and separated from the other clustered coun-
terpart. We defined our TGF-b-responsive SCC-SC signature as
genes whose transcripts at an FPKMR 1 were differentially ex-
pressed by log2 fold changeR j1j and which displayed a statisti-
cal significance (p < 0.05, q < 0.05) acrossdatasets.Our signature
consisted of 632 up- and 478 downregulated genes (Figure S4D).
Several noteworthy alterations were immediately evident in the
TGF-b signature. Consistent with our findings thus far, cancer-
related differentiation genes, e.g.Krt13, were upregulated. As ex-
pected, there was significant overlap with prior signatures from
purified SCC-SCs but independent of TGF-b status (Schober
and Fuchs, 2011; Lapouge et al., 2012). Notably however, Sox2,
Pitx1, Vegfa and other genes typifying these SCC-SC signatures
(Boumahdi et al., 2014; Siegle et al., 2014) were more enriched
in theTGF-b reporter+ subset than in the total basalSCpopulation.
Figure 4. TGF-b-Responding SCC-SCs Show Enhanced Drug Resistance In Vivo
(A) Immunodetection of AcCasp3 (green) and TGF-b reporter (red) in tumors frommice administrated with saline or cisplatin. (Right) Quantifications revealing that
TGF-b signaling protected basal tumor cells from cisplatin-induced apoptosis. (3 tumors analyzed; >15 microscopic image fields per tumor).
(B) Experimental scheme and representative examples of lineage tracing to monitor the fate of the TGF-b reporter+ subset of basal tumor cells after cisplatin
treatment. (Right) Note that resistant SCCs are largely contributed by TGF-b-responding cells that survived cisplatin.
(C) Quantifications show that the % of YFP+ basal tumor cells increases after cisplatin, suggestive of their preferential survival.
(D) Quantifications of basal tumor cells in G2/M phase (phospho-H3+) that are YFPneg vs YFP+ (left) and reporterneg vs reporter+ (right). Note: although proliferation
of basal tumor cells that resist cisplatin is generally elevated, TGF-b-responding SCC-SCs are still slower-cycling.
(E) Recurring tumor clones that resist cisplatin are largely YFP+ and express little K10, consistent with their derivation from TGF-b reporter+ basal cells.
(F) Quantification of apoptotic cells in cisplatin-treated tumors from LV-transduced Tgfbr2+/fl or Tgfbr2fl/fl mice treated as in (B). Note enhanced survival of TbRII+
progenies.
(G andH) Quantification of AcCasp3+ cells after cisplatin treatment of xenografts of (G) TGF-b reporter transduced humanSCC cells (reporter+ vs reporterneg), and
(H) xenografts pre-treated ± LY364947 (reporter+ vs reporterdim) (n>3).
Data are box-and-whisker plots (C–F) and mean ± SEM (G and H). Scale bars, 50 mm. See also Figure S3.There was also overlap (28%) between our TGF-b reporter+ SCC
basal cell RNA-seq and the signature obtained from VEGF-over-
expressing papilloma basal cells (Beck et al., 2011).
Gene ontology (GO) term analysis provided insights into bio-
logical processes enriched in TGF-b-responding SCC-SCs. In
addition to epidermal development; lipid metabolism; and cell
proliferation, ‘‘reduction and oxidation’’ (Redox) genes sur-faced among top GO-terms. This was especially interesting
given that the top upregulated gene pathway in KEGG analysis
was ‘‘glutathione metabolism’’ (Figure 5A). Notably, glutathione
is themost abundant intracellular antioxidant in animal cells and
involves two important metabolic processes (Figure 5B) (Lush-
chak, 2012). The first is a reduction reaction, which prevents
damage from reactive oxygen species (ROS) by exhaustingCell 160, 963–976, February 26, 2015 ª2015 Elsevier Inc. 969
Figure 5. Transcriptional Profiling Reveals a Link between TGF-b Signaling and Glutathione Metabolism
(A) Summary of transcriptional profiling of TGF-b reporter+ vs reporterneg tumor basal cells by RNA-seq. Significantly upregulated genes are listed on the right
side; note genes involved in glutathione metabolism (red), Redox (asterisk). Other genes relevant to text are bolded. (Bottom) Gene ontology (GO: biological
function) and KEGG pathway analyses.
(B) Schematic of glutathionemetabolic pathway: 1) Reduction reaction; 2) Conjugation reaction. Genes in red are significantly upregulated in TGF-b reporter+ SCs.
(C) RNA-seq validation by qRT-PCR of independently derived in vivo tumor basal cell RNA samples. Data are mean ± SEM.
(D) Flow cytometry analysis of ROS levels in basal cells in normal skin epidermis and tumor epithelia ± TGF-b reporter activity. See also Figure S4.ROS through the conversion of reduced glutathione (GSH)
to its oxidized state (glutathione disulfide, GSSG). The second
key process is a conjugation reaction regulated by glutathione
S-transferase (GST), which is known to metabolize cisplatin
(Kelland, 2007).
Our RNA-seq data indicated that genes involved in GSH-
conjugation, GSH-mediated reduction and GSH-recycling pro-
cesses were broadly upregulated in TGF-b reporter+ SCs. This
list included GST genes (Gsta1-5, Gsto1) (Figure 5A). qRT-PCR
on RNAs from independent tumor samples confirmed their
enhanced expression in TGF-b reporter+ basal tumor cells (Fig-
ure 5C). Moreover, as judged by CellROX green, a cell-permeant
dye that is brightly fluorescent only upon oxidation by ROS, ROS
levels were significantly lower in TGF-b reporter+ tumor cells,
consistent with the high expression of genes involved in gluta-
thione metabolism (Figure 5D).
TGF-b Induces p21 which In Turn Stabilizes and
Activates NRF2-Dependent Transcription in SCC-SCs
The myriad of glutathione metabolism genes upregulated
in TGF-b-responding SCC-SCs necessitated further insights970 Cell 160, 963–976, February 26, 2015 ª2015 Elsevier Inc.before we could abrogate the pathway and assess the conse-
quences to cisplatin resistance. Interestingly, the enhancer/pro-
moters of these genes contained antioxidant response elements
(AREs), which are the consensus binding motifs for transcription
factor NRF2 (Gorrini et al., 2013) (Figure 6A). Additionally, as
judged by immunofluorescence, nuclear NRF2 was prominent
in TGF-b reporter+ cells at the tumor-stroma interface (Figure 6B).
However, neither RNA-seq nor qRT-PCR data showed TGF-b re-
porter-dependent differences in NRF2 gene (Nfe2l2) transcrip-
tion (Figure 6A), indicating that other steps must be involved in
upregulating the antioxidant gene response in this SCC-SC
subset.
Probing mechanism, we first considered KEAP1, which nor-
mally binds to and targets NRF2 for proteosome-mediated
degradation. TGF-b activity did not affect Keap1 mRNA levels,
diminishing the likelihood that KEAP1 absence might underlie
NRF2 stabilization. By contrast, cyclin-dependent kinase inhibi-
tor p21 purportedly competes with KEAP1 for NRF2 binding
(Chen et al., 2009), and Cdkn1a, encoding p21, is an established
target of TGF-b–SMAD signaling (Seoane et al., 2004; Koinuma
et al., 2009). Indeed, RNA-seq and qRT-PCR showed Cdkn1a
Figure 6. TGF-b Target p21 Is Required for NRF2-Dependent Activation of Antioxidant Genes
(A) Nucleotide sequence of NRF2 binding motifs within the 50-upstream region ofGst and other NRF2 target genes. Nucleotides in capital letters are those shared
by the antioxidant response element (ARE) consensus sequence. (bottom) qRT-PCR analysis of in vivo tumor basal cell RNA samples. Data are mean ± SEM.
(B and C) Co-expression of NRF2 or p21 (green) and TGF-b reporter (NLS-mCherry) at tumor-stroma interface of TbRII+ tumor sections. Fluorescent intensities of
NRF2 and p21 staining in TGF-b reporter+ and reporterneg cells were quantified (NRF2: n=78 and 57 cells, p21: n=101 and 71 cells). Data are box-and-whisker
plots.
(D) Immunoblotting of lysates prepared from HRasG12V-overexpressing TbRII+ 10MKs stimulated with TGF-b1 for indicated times.
(E) Immunoblotting of lysates prepared from HRasG12V-overexpressing TbRII+ and TbRIIneg 10MKs stimulated with TGF-b1 for 36 hr.
(F) Immunoblotting of lysates prepared from 36 hr TGF-b1-treated HRasG12V-overexpressing 10MKs transduced with scramble, Cdkn1a or Nfe2l2 shRNAs.
(G) LV NRF2-ARE reporter. (Right) Immunofluorescence and immunoblots of NRF2-reporter transduced HRasG12V-induced MKs expressing scramble (control),
Cdkn1a, Nfe2l2, or Maff (control) shRNAs ± TGF-b1 stimulation (36 hr). Note that ARE-reporter activity is abolished upon Cdkn1a or Nfe2l2 but not control KD.
Scale bars, 50 mm. See also Figure S5.mRNAwas upregulated in TGF-b reporter+ SCC-SCs in vivo (Fig-
ure 5A and 6A). Immunofluorescence further revealed a strong
correlation between TGF-b signaling activity and p21 expression
at the tumor-stroma interface (Figure 6C). Moreover, whereas
NRF2 and p21 were readily detected in TGF-b-responding
tumor cells at the tumor-stromal interface, their expression
was not seen in neighboring TbRIIneg tumor cells derived from
TGFb-CreER activation nor in early papillomas, which do not
show appreciable TGF-b signaling (Figures S5A–S5C). In vitro
studies corroborated these findings (Figure S5D).
Delving deeper, we treated HRasG12V-transformed 10MKs
with TGF-b1 and then checked by qRT-PCR for temporalchanges in levels of select mRNAs (Figures S5E and S5F). In
contrast to Nfe2l2, whose transcripts remained constant during
the experiment, Cdkn1a transcripts rose 1–3 hr after TGF-b1
treatment, reaching 5X normal levels by 48 hr. Moreover by
immunoblot, NRF2 and p21 were elevated upon prolonged
TGF-b stimulation (Figure 6D). These effects were abrogated in
TbRIIneg HRasG12V 10MKs (Figure 6E), supporting the view that
p21 induced by TGF-b/pSMAD2 signaling mediates NRF2 pro-
tein stabilization.
To rigorously test the hierarchical relation between TGF-b, p21
and NRF2, we used LVs harboring Cdkn1a and Nfe2l2 shRNAs
(Figure S5G). Cdkn1a shRNAs not only efficiently depleted p21Cell 160, 963–976, February 26, 2015 ª2015 Elsevier Inc. 971
Figure 7. TGF-b-Induced Glutathione Metabolism Confers Enhanced Anti-Cancer Drug Resistance In Vivo
(A) Coimmunolabeling of TGF-b reporter and GSTa in representative sections of SCCs from LV-transduced mice. Note that nuclear TGF-b reporter signal (red)
and cytoplasmic GSTa (green) overlap in invasive cells at the tumor-stroma interface.
(B) Immunofluorescence of TbRII+ tumor sections from transductions of our LV reporter harboring scramble control or Cdkn1a shRNAs. p21 (green)
correlates well with TGF-b reporter activity (red) in scramble control and is silenced by Cdkn1a shRNA expression.
(C) Quantifications of GSTa immunofluorescence intensities of TGF-b reporter+ and reporterneg basal tumor cells of mice transduced with scramble, Cdkn1a or
Nfe2l2 shRNAs (n=144, 145 or 121 cells).
(D) Quantifications of proliferation (pH3+) and apoptosis (AcCasp3+) in basal cells from HRasG12V-derived SCCs of mice transduced with LVs harboring scramble
control, Cdkn1a, or Nfe2l2 shRNAs.
(E) Coimmunolabeling and quantifications (n=3 tumors, >16 microscopic image fields) of AcCasp3 (green, cytoplasmic) and TGF-b reporter activity (red, nuclear)
in Cdkn1a or Nfe2l2 KD basal cells of SCCs from cisplatin-treated mice. Yellow arrowheads denote double-labeled cells. Note that without p21 or NRF2, TGF-b
reporter+ cells are no longer able to resist apoptosis in response to cisplatin.
(F) TGF-b1-pretreatedMKs were exposed to cisplatin ± a potent GST inhibitor, ethacrynic acid. Note that most YFPnegTbRII+ MKs (red arrowheads) still exhibited
robust TGF-b reporter activity, but now showed apoptotic rounding like their YFP+TbRIIneg counterparts.
(G and H) KEAP1 stabilizes NRF2 in TbRIIneg SCC-SCs and renders them resistant to cisplatin. (G) Immunoblotting of lysates prepared from HRasG12V-over-
expressing 10MKs transduced with scramble or Keap1 shRNAs. (middle) qRT-PCR of NRF2-reporter (mCherry mRNA) expression. (right) NRF2 immunofluo-
rescence (green) in either scramble- orKeap1 shRNA-transduced (H2B-RFP+) TbRIIneg cells. Note that NRF2 is readily detected in TbRIIneg cells only if transduced
(legend continued on next page)
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but also reduced NRF2 protein in TGF-b stimulated cells (Fig-
ure 6F). By contrast, Nfe2l2 depletion did not affect p21 levels
induced by TGF-b/pSMAD2 signaling. These data place p21
downstream of TGF-b signaling and upstream of NRF2 sta-
bilization. Indeed, as judged by immunoprecipitation, the inter-
action between p21 and NRF2 was dependent upon TGF-b1
(Figure S5H).
To test the functional significance of this hierarchical relation,
we created a LV NRF2 reporter (Figure 6G). NRF2 reporter activ-
ity was potently induced in 10MKs not only by the classical ROS,
hydrogen peroxide (H2O2) (Figure S5I) but also by TGF-b stimu-
lation (Figure S5J). Comparative analyses showed that while not
as robust as the maximal effect achieved with 500 mMH2O2, the
effects of TGF-b1 were comparable to 100–200 mM H2O2 (Fig-
ure S5J). Moreover, NRF reporter activation by either H2O2 or
TGF-b1 was abolished when these cells were transduced with
LVs harboring Cdkn1a or Nfe2l2 shRNAs (Figures 6G and S5K).
Together, these results provide compelling evidence that p21
is required for the NRF2-mediated target gene expression that
occurs downstream of TGF-b/pSMAD2 signaling in SCC-SCs.
A Role for Glutathione Metabolism in the Cisplatin
Resistance of TGF-b-Responding SCC-SCs
To address the physiological relevance of the p21/NRF2
pathway that we unearthed in vitro, we first showed that GSTa,
one of the highly upregulated glutathione pathway genes, was
indeed upregulated at the protein level in TGF-b reporter+ cells
at the tumor-stroma interface of invasive SCCs (Figure 7A). To
test whether p21 mediates TGF-b-induced drug resistance, we
conducted in vivo KDs by introducing Cdkn1a shRNAs into our
LV TGF-b reporter constructs (Figure 7B). In Cdkn1a KD tumors,
p21 expression was abrogated in TGF-b reporter+ cells. Impor-
tantly, GSTa was also downregulated upon Cdkn1a KD (Fig-
ure 7C). Similar results were seen in tumors with Nfe2l2 KD
(shown). Together, these findings showed that a key component
of glutathione metabolism was dependent upon NRF2 and
TGF-b-regulated Cdkn1a.
Notably, the slow-cycling behavior of TGF-b-responding
SCC-SCs was not affected appreciably by loss of either p21 or
NRF2 (Figure 7D), providing a means of selectively reducing
glutathione metabolism without compromising slow-cycling
status in TGF-b-responding SCC-SCs. We therefore proceeded
to address whether Cdkn1a and Nfe2l2 KD would affect their
cisplatin resistance. In the scramble control, TGF-b-responding
SCC-SCs showed little apoptosis. In contrast, when mice
bearing tumors knocked down for either Cdkn1a or Nfe2l2
were treated with cisplatin, many basal tumor cells were dou-
ble-positive for AcCasp3 and TGF-b-reporter (Figure 7E). Simi-
larly, drug inhibition of GST increased the sensitivity of TGF-
b-responding tumor cells to cisplatin in vitro (Figure 7F). Thus,
under circumstances where SCC-SCs were still slow-cycling
and responsive to TGF-b, the normalization of glutathione meta-with Keap1 shRNA. (H) Immunofluorescence of transduced YFP+TbRIIneg HRa
suppresses apoptotic rounding. (right) Quantifications of AcCasp3+ cells in the s
(I) Anti-NRF2 (green) co-immunolabeling of Keap1 KD (H2B-RFP+) cells in TbRIIn
(J) AcCasp3+ quantifications show that Keap1 but not scramble shRNA protects
Data are box-and-whisker plots (C, D, H and J) and mean ± SEM (E and G). Scabolism was sufficient to abolish the survival advantage of TGF-b
responding basal cells to cisplatin treatment.
Finally, we addressed the converse, namely whether by
enhancing NRF2 stabilization, we could confer enhanced resis-
tance of TbRII-null SCC-SCs to cisplatin. In vitro, both NRF2
protein and NRF2 reporter activity rose in TbRII-null HRasG12V-
transformed MKs transduced by either of two different Keap1
shRNAs (Figure 7G). Correspondingly, this resulted in enhanced
resistance to cisplatin (Figure 7H). When equal numbers of non-
transduced and either scramble- or Keap1 shRNA-transduced
TbRII-null HRasG12V-transformed MKs were mixed and then en-
grafted in vivo, tumors arose which displayed increased NRF2
specifically in Keap1 shRNA-transduced MKs (Figure 7I). Most
importantly, fewer of these basal tumor cells apoptosed after
cisplatin treatment (Figure 7J). Overall, these data underscore
the importance of this pathway in imparting enhanced drug
resistance to TGF-b-responding SCC-SCs.
DISCUSSION
Functional and phenotypic heterogeneity among tumor cells
have long been recognized, and dynamic changes in genetic,
epigenetic, tumor microenvironmental and systemic factors
affect subpopulations of tumor cells to acquire advantages for
proliferation, survival, spread, and resistance to anti-cancer
therapeutics. In studying stem cells of SCCs, we realized that
they vary in cycling rates, and that SC numbers increase when
TGF-b signaling is abrogated. These findings raised the possibil-
ity that TGF-b signaling might be at the root of tumor heteroge-
neity and that it might impact directly on cancer SCs.
In the present study, we established an in vivo LV delivery sys-
tem, which allowed us to address roles of TGF-b signaling in the
early stages of tumor progression. Our findings provide compel-
ling in vivo evidence of TGF-b’s contributions to the emergence
of tumor heterogeneity in the tumor-initiating cells that drive
SCC. The heterogeneity in TGF-b-responsiveness is rooted in
the congregation of myeloid cells near the tumor vasculature.
While TGF-b is secreted in a latent form and deposited in
ECM, TGF-b can be activated and released by a variety of
mechanisms, which include activated integrins. The paracrine
activation of TbRI/II-pSMAD2 in a subset of nearby (integrinhi)
SCC-SCs reflected active TGF-b signaling in these cells.
TGF-b represses normal epithelial growth, thereby functioning
as an early tumor suppressor. These effects have been exten-
sively studied, as have TGF-b’s late-stage roles in metastasis.
However, in the absence of tools to explore intermediate stages
of primary tumor progression, the prior speculation as to TGF-b’s
dual function in these intermediate steps has been that TGF-b’s
cytostatic effects are lost during tumor progression due to acti-
vation of oncogenic pathways such as Ras-MAPK, PI3K and
c-Myc, which then override TGF-b’s growth inhibitory effects
(Chen et al., 2002; Seoane et al., 2004; Gomis et al., 2006; BrunasG12V-MKs treated with cisplatin for 10 hr. Note that Keap1 KD (H2B-RFP+)
ame experiment.
eg HRasG12V allograft tumors.
TbRIIneg HRasG12V allograft SCC-SCs against cisplatin.
le bars, 50 mm. See also Figure S6.
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et al., 2007). At later stages, other TGF-b responses then pur-
portedly prevail that are unrelated to TGF-b’s cytostatic effects
but which favor tumor invasion and metastasis.
By designing a functional TGF-b reporter system and coupling
Cre activity to TGF-b signaling, we could monitor and compare
the behaviors and fates of the subset of basal tumor SCs that
activate TbRI/II-pSMAD2 signaling (or which we blocked from
doing so) in developing tumors expressing HRasG12V, commonly
mutated in human skin cancers. Our lineage tracing analyses
of the clonal growth of these cells revealed clearly that TGF-b’s
cytostatic and tumor-promoting effects are not mutually exclu-
sive. Rather, TGF-b-responding cells display morphological
and biochemical features of invasiveness and malignant conver-
sion during a period when they are in a slow-cycling proliferation
state. Moreover, and most importantly, our findings show that
these slow-cycling invasive tumor cells gain amarked advantage
over hyperproliferative, more tightly clustered TbRII-null SCC-
SCs in that they are better protected against DNA damaging
agents such as cisplatin.
Cisplatin resistance is a hallmark of head and neck SCCs.
Suggested mechanisms for resistance include reduced drug up-
take, increased drug efflux, inactivation by GSH conjugation,
increased DNA damage repair, and failure to induce apoptosis
(Kelland, 2007). Another proposed route is the failure of anti-can-
cer therapies to target slower-cycling cancer SCs (Meacham
andMorrison, 2013). Since our results show that TGF-b reporter+
skin tumor cells are indeed slower-cycling, it seemed plausible
that at least in part, the enhanced protection against anti-prolif-
erative cancer drugs might be attributable to the slower-cycling
status of TGF-b-responding SCs. However as we learned, this
was only the tip of the iceberg in what TGF-b responsiveness
is able to achieve, and in fact slower-cycling status appears to
be secondary to SCC-SC drug resistance.
Given that the alterations provoked by TGF-b in SCC-SCs
extended beyond cycling rates, we asked whether additional
changes in transcriptomes might explain the enhanced resis-
tance of TGF-b-responding SCC-SCs to cisplatin. The TGF-b
signature encompassed genes already known to play a key
role in stemness. However, the signature also show-cased
genes involved in glutathione metabolism. Delineating mecha-
nism, TGF-b inducedCdkn1a transcription, leading to p21-medi-
ated NRF2 stabilization and induction of a cohort of glutathione
metabolism genes. Most importantly, when Cdkn1a or Nfe2l2
were knocked down, SCC-SCs were still responsive to TGF-b
and were still slower-cycling, but their survival in the face of
cisplatin was normalized. Further bolstering the importance of
this pathway, KD of Keap1 in TbRII-null SCs resulted in not
only enhanced NRF2 target gene activity but also enhanced
survival in cisplatin treated SCCs.
The role of enhancing antioxidant reactions and glutathione
metabolism is still obscure. Although inflammatory cells can
have anti-tumorigenic roles, they can also release ROS, which
is actively mutagenic, thereby accelerating the genetic evolution
of nearby cancer SCs (Grivennikov et al., 2010). In the present
study, we showed that even though immune cells concentrate
near the vasculature, ROS levels are preferentially reduced in
the subset of TGF-b-responding SCC-SCs, and that this is attrib-
utable to the TGF-b/p21/NRF2 pathway we delineated here.974 Cell 160, 963–976, February 26, 2015 ª2015 Elsevier Inc.In closing, since not all tumor-initiating cells localize to the
perivasculature where TGF-b is concentrated, our studies
show that this can be advantageous to the tumor. On the one
hand, SCC-SCs that do not respond to TGF-b are faster-cycling
and can greatly accelerate tumor growth and differentiation. On
the other hand, TGF-b-responding SCC-SCs cycle more slowly
but show enhanced invasiveness and increased glutathione
metabolism, thereby increasing the likelihood not only of metas-
tasis but also long-term survival in the face of ROS and anti-can-
cer drugs. Given that perivasculature is an emerging niche for
many types of SCs, it will be interesting to see in the future if
the mechanisms we’ve unearthed here will extend to other can-
cers. It will also be important to know whether these mecha-
nisms are operative in human SCCs. In this regard, an analysis
of the TCGA database revealed poor prognosis for patients
with SCCs that upregulate this cohort of glutathione metabolism
genes (Figure S6). Whether these tantalizing parallels between
mouse and human SCCs will continue to hold must await future
cancer databases on tumor-initiating cells as opposed to whole
tumor samples. If so, these hitherto underappreciated roles for
TGF-b signaling in tumor heterogeneity and anti-cancer resis-
tance could serve as a foundation for designing chemotherapeu-
tics that might overcome drug resistance for this devastating
cancer.
EXPERIMENTAL PROCEDURES
In Vivo LV Transduction, Tumor Formation, and Drug Treatment
LV production, concentration, and ultrasound-guided in utero transduction
were performed as described (Beronja et al., 2010). Briefly, female mice at
day 9.5 of gestation were anesthetized with isoflurane (Hospira). In utero,
0.5 ml LV was microinjected into each embryo’s amniotic sac. To induce tumor
formation, rtTA3 was activated by feeding adult mice with Doxy (2 mg/kg)
chow. Cre was activated by intraperitoneal (i.p.) injection of Tam (Sigma) in
corn oil: TGFb-CreER, 25 mg/g low-dose, 3 X 100 mg/g high-dose; K14-CreER,
17.5 mg/g. Cisplatin (Sigma) was dissolved in saline (1 mg/ml) and adminis-
trated by i.p. injection (10 mg/kg). TbRI kinase inhibitor (LY364947, Tocris)
was i.p. injected (1 mg/kg), 3X/wk. For limit-dilution transplantation and xeno-
transplantation, 1.03 103–105 mouse primary tumor cells and 1.03105 human
SCC cells were subcutaneously injected with Matrigel (BD) in Nude mice.
Tumor size was calculated using the formula 4/3p 3 L/2 3 W/2 3 D/2. For
cell proliferation analysis in vivo, BrdU (50 mg/g) or EdU (25 mg/g) was injected
i.p. 4 or 12 hr before lethal administration of CO2. All procedures were per-
formed with IACUC-approved protocols.
In Vitro Cell Culture Experiments
Cells were cultured in E medium with 15% fetal bovine serum (FBS) and 50 mM
CaCl2 (1
0MKs) or 1.5 mM CaCl2 (human SCC lines) at 37
C, 7.5% CO2. For
stimulation experiments, media were supplemented with either recombinant
mouse TGF-b1 (100 pM = 2.5 ng/ml, R&D Systems), 4-hydroxytamoxifen
(1 mM, Sigma), cisplatin (20 mM, Sigma), H2O2 (1–1,000 mM, Fisher), or
ethacrynic acid (50 mM, Abcam). For colony formation assay, FACS-isolated
1.03104 a6hiCD44+mCherryneg and a6hiCD44+mCherry+ primary tumor basal
cells were plated onto mitomycin-treated mouse 3T3 fibroblasts in 6-well
dishes in E medium with 15% FBS and 300 mM CaCl2. Colony number was
counted after 14 day culture.
Statistics
Data were analyzed and statistics performed (unpaired two-tailed Student’s t
test) in Prism5 (GraphPad). Significant differences between two groups were
noted by asterisks or actual p values (*p < 0.05; **p < 0.01; ***p < 0.001). Quan-
tification data were presented inmean value ± SEM or in box and whisker plots
with the dimensions of the box encompassing the 25th–75th percentile, the
horizontal bar representing the median, and the error bars representing mini-
mum and maximum values.ACCESSION NUMBERS
RNA-seq data have been submitted to NCBI-GEO under the accession num-
ber GSE64867.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and five movies and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2015.01.043.
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